Adriel Perez, APRN
Family · Oviedo, FLNPI 1083276158
Payments from drug & device makers
Across 526 payments — averaging $18.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Insulet Corporation$1K
- Lilly USA, LLC$1K
- Boehringer Ingelheim$724
- IBSA Pharma Inc.$673
- Xeris Pharmaceuticals, Inc.$649
- plus $4K from 31 others
What the payments were for
- Food & beverage$9,85399%
- Education$741%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 88 | $1,422 |
| Insulet Corporation | 49 | $1,367 |
| Lilly USA, LLC | 51 | $1,036 |
| Boehringer Ingelheim | 47 | $724 |
| IBSA Pharma Inc. | 50 | $673 |
| Xeris Pharmaceuticals, Inc. | 34 | $649 |
| Sanofi-aventis U.S. LLC | 23 | $419 |
| Amarin Pharma, Inc. | 31 | $404 |
| Amgen | 19 | $402 |
| AstraZeneca | 22 | $382 |
| Bayer | 14 | $288 |
| Corcept Therapeutics | 11 | $287 |
| Amneal Pharmaceuticals LLC | 14 | $269 |
| Edwards Lifesciences | 1 | $154 |
| Tandem Diabetes Care, Inc. | 3 | $131 |
| Endo Pharmaceuticals Inc. | 7 | $127 |
| Esperion Therapeutics, Inc. | 5 | $126 |
| Dexcom, Inc. | 6 | $124 |
| Merck | 6 | $109 |
| Radius Health, Inc. | 4 | $93 |
| Novartis | 4 | $89 |
| Cequr Corporation | 6 | $87 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $84 |
| AbbVie | 4 | $72 |
| Kowa Pharmaceuticals America, Inc. | 5 | $72 |
| Zealand Pharma US, Inc. | 3 | $70 |
| GRT US Holding, Inc. | 2 | $46 |
| Mannkind Corporation | 2 | $38 |
| Currax Pharmaceuticals LLC | 2 | $31 |
| Clarus Therapeutics Inc. | 2 | $30 |
| Impulse Dynamics (USA) Inc. | 1 | $24 |
| Antares Pharma, Inc. | 1 | $20 |
| Philips North America LLC | 1 | $20 |
| Vistapharm, Inc. | 1 | $17 |
| Lifescan, Inc. | 1 | $16 |
| Renalytix AI, Inc. | 1 | $15 |
| Acerus Pharmaceuticals Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,927 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 124 | $154,139 |
| MounjaroTirzepatide | 92 | $110,194 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 36 | $41,778 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $39,486 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $25,218 |
| TrulicityDulaglutide | 16 | $20,259 |
| JardianceEmpagliflozin | 15 | $18,507 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $15,479 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $2,957 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 25 | $2,449 |
| UnithroidLevothyroxine Sodium | 39 | $2,033 |
| SynthroidLevothyroxine Sodium | 11 | $1,430 |
| Levothyroxine Sodium | 41 | $426 |
| Metformin Hcl ErMetformin Hcl | 34 | $212 |
| Metformin Hcl | 24 | $188 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,422 | $154,139124 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,036 | $130,453108 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance | $724 | $60,28551 claims |
| Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium | $269 | $2,45980 claims |
| AbbVieSynthroid | $72 | $1,43011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.
Other family in Oviedo
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.